{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.6","upperLimit":"96.4","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"RFS is defined as the time between the date of first dose until relapse or death from any cause, whichever occurs first. RFS is calculated for all participants in Phase 2 Cohort 2. 4-Month RFS rate is defined as the percentage of participants in Phase 2 Cohort 2 who have not relapsed or died on or before their 4-month response evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with AML in morphologic complete remission (CR)/ complete remission with incomplete blood count recovery (CRi) after prior therapy with residual isocitrate dehydrogenase 1 (\\[IDH1\\]-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 2; FT-2102 (Single Agent)"}],"paramType":"NUMBER","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102. This outcome measure is applicable for Cohort 2.","reportingStatus":"POSTED","timeFrame":"Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)","title":"Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}